Treatment Response and Prophylactic Cranial Irradiation Are Prognostic Factors in a Real-life Limited-disease Small-cell Lung Cancer Patient Cohort Comprehensively Staged With Cranial Magnetic Resonance Imaging

被引:24
作者
Eze, Chukwuka [1 ]
Roengvoraphoj, Olarn [1 ]
Niyazi, Maximilian [1 ]
Hildebrandt, Guido [2 ]
Fietkau, Rainer [3 ]
Belka, Claus [1 ,4 ]
Manapov, Farkhad [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Radiat Oncol, Munich, Germany
[2] Univ Rostock, Dept Radiat Oncol, Rostock, Germany
[3] Friedrich Alexander Univ Erlangen Nuernberg, Dept Radiat Oncol, Erlangen, Germany
[4] German Ctr Lung Res, Comprehens Pneumol Ctr, Munich, Germany
关键词
Brain metastasis; Chemoradiotherapy; PCI; SCLC; Survival; GROUP POOLED ANALYSIS; COMPLETE REMISSION; BRAIN METASTASES; SURVIVAL; CHEMORADIOTHERAPY; CARCINOMA; FAILURE; RISK;
D O I
10.1016/j.cllc.2016.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the effect of prophylactic cranial irradiation (PCI) in patients with disease that responded to therapy, we reviewed 184 limited-disease small-cell lung cancer patients comprehensively staged by contrastenhanced cranial magnetic resonance imaging. Treatment response and PCI strongly correlated with prolonged overall survival, time to progression, and brain metastasise-free survival. Introduction: Prophylactic cranial irradiation (PCI) has proven to decrease the incidence of brain metastases (BMs), with a modest improvement in survival. Patients and Methods: The impact of PCI was evaluated in 184 patients treated with chemoradiotherapy. PCI was applied to patients with disease with partial and complete response only when cranial magnetic resonance imaging before and after primary treatment revealed no BMs. Correlation between PCI and overall survival (OS), BM-free survival (BMFS), and time to progression (TTP) was analyzed to describe survival within subgroups. Results: Concurrent and sequential chemoradiotherapy was applied in 71 patients (39%) and 113 patients (61%), respectively. Seventy-one patients (39%) with partial and complete response were treated with PCI. Metachronous BMs were detected in 16 (23%) of 71 patients in the PCI group compared to 42 (37%) of 113 patients in the non-PCI group. Median BMFS in the PCI group was not reached; it was 23.6 months in the non-PCI group. Median OS and TTP were 26 months (range, 19.4-32.6 months) in the PCI group versus 14 months (range, 11.4-16.6 months) in patients without PCI whose disease responded to therapy versus 9 months in patients with disease that did not respond to therapy (P < .0001), and 27 versus 14.5 months (range, 9.0-19.9 months) versus 8.8 months (range, 7.7-9.9 months) (P < .0001) in the PCI group versus those with response without PCI versus those with nonresponse. The effect of PCI was independent of gender. On multivariate analysis, PCI was a variable correlating with OS (hazard ratio = 1.899; 95% confidence interval, 1.370-2.632; P < .0001) and TTP (hazard ratio = 2.164; 95% confidence interval, 1.371-3.415; P = .001) after adjustment for other prognostic factors. Conclusion: In real-life patients comprehensively staged with cranial magnetic resonance imaging, treatment response and PCI strongly correlated with prolonged OS, TTP, and BMFS.
引用
收藏
页码:E243 / E249
页数:7
相关论文
共 24 条
[1]   Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].
Aupérin, A ;
Arriagada, R ;
Pignon, JP ;
Le Péchoux, C ;
Gregor, A ;
Stephens, RJ ;
Kristjansen, PEG ;
Johnson, BE ;
Ueoka, H ;
Wagner, H ;
Aisner, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484
[2]   Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure? [J].
Brade, AM ;
Tannock, IF .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1020-1022
[3]   Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database [J].
Govindan, Ramaswamy ;
Page, Nathan ;
Morgensztern, Daniel ;
Read, William ;
Tierney, Ryan ;
Vlahiotis, Anna ;
Spitznagel, Edward L. ;
Piccirillo, Jay .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4539-4544
[4]   BRAIN METASTASES IN PATIENTS WITH LIMITED SMALL CELL LUNG-CANCER ACHIEVING COMPLETE REMISSION - CORRELATION WITH TNM STAGING [J].
ICHINOSE, Y ;
HARA, N ;
OHTA, M ;
MOTOHIRO, A ;
HATA, K ;
YAGAWA, K .
CHEST, 1989, 96 (06) :1332-1335
[5]   Small-cell lung cancer [J].
Jackman, DM ;
Johnson, BE .
LANCET, 2005, 366 (9494) :1385-1396
[6]  
KOMAKI R, 1981, CANCER TREAT REP, V65, P811
[7]   Primary tumor response to chemoradiotherapy in limited-disease small-cell lung cancer correlates with duration of brain-metastasis free survival [J].
Manapov, Farkhad ;
Kloecking, Sabine ;
Niyazi, Maximilian ;
Levitskiy, Victor ;
Belka, Claus ;
Hildebrandt, Guido ;
Fietkau, Rainer ;
Klautke, Gunther .
JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (02) :309-314
[8]   Prevalence of brain metastases immediately before prophylactic cranial irradiation in limited disease small cell lung cancer patients with complete remission to chemoradiotherapy: A single institution experience [J].
Manapov, Farkhat ;
Klautke, Gunther ;
Fietkau, Rainer .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) :652-655
[9]   Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis [J].
Meert, AP ;
Paesmans, M ;
Berghmans, T ;
Martin, B ;
Mascaux, C ;
Vallot, F ;
Verdebout, JM ;
Lafitte, JJ ;
Sculier, JP .
BMC CANCER, 2001, 1 (1)
[10]   IMPORTANCE OF TIMING FOR THORACIC IRRADIATION IN THE COMBINED MODALITY TREATMENT OF LIMITED-STAGE SMALL-CELL LUNG-CANCER [J].
MURRAY, N ;
COY, P ;
PATER, JL ;
HODSON, I ;
ARNOLD, A ;
ZEE, BC ;
PAYNE, D ;
KOSTASHUK, EC ;
EVANS, WK ;
DIXON, P ;
SADURA, A ;
FELD, R ;
LEVITT, M ;
WIERZBICKI, R ;
AYOUB, J ;
MAROUN, JA ;
WILSON, KS .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :336-344